Year |
Citation |
Score |
2020 |
Viswanadhapalli S, Ma S, Lee TK, Liu X, Kassees K, Pratap UP, Liu J, Tang W, Tekmal RR, Ahn J, Raj GV, Vadlamudi RK. Abstract 5676: Preclinical evaluation of estrogen receptor coregulator binding inhibitor ERX-245 in breast cancer Cancer Research. 80: 5676-5676. DOI: 10.1158/1538-7445.Am2020-5676 |
0.338 |
|
2019 |
Raj GV, Liu X, Ekoue D, Ahn J, Vadlamudi R. Abstract 26: Development of potent lead compounds in multiple tumor types Cancer Research. 79: 26-26. DOI: 10.1158/1538-7445.Sabcs18-26 |
0.321 |
|
2017 |
Raj GV, Sareddy GR, Ma S, Lee T, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen C, Lee W, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, ... ... Ahn J, et al. Author response: Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers Elife. DOI: 10.7554/Elife.26857.081 |
0.352 |
|
2016 |
Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, Brown AJ, Zhou C, Deng J, Wang MW. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews. 68: 954-1013. PMID 27630114 DOI: 10.1124/pr.115.011395 |
0.368 |
|
2016 |
Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T, Ma S, Lee WR, Mann M, Krishnan SR, Gonugunta V, Strand DW, Tekmal RR, Ahn J, Raj GV. Abstract B08: ESR1 coregulator binding site inhibitors (ECBIs) as novel therapeutics to target hormone therapy-resistant breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B08 |
0.305 |
|
2016 |
Vadlamudi RK, Sareddy GR, Viswanadhapalli S, Lee T, Ma S, Lee WR, Mann M, Krishnan SR, Gonugunta V, Liu Y, Strand DW, Tekmal RR, Ahn J, Raj GV. Abstract 860: ESR1 coregulator binding inhibitor (ECBI): a novel agent for treating hormone therapy-resistant breast cancer Cancer Research. 76: 860-860. DOI: 10.1158/1538-7445.Am2016-860 |
0.319 |
|
2011 |
Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, Ahn JM, Kiesewetter DO, Chen X. PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue. Molecular Pharmaceutics. 8: 1775-82. PMID 21800885 DOI: 10.1021/mp200141x |
0.667 |
|
2010 |
Murage EN, Gao G, Bisello A, Ahn JM. Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. Journal of Medicinal Chemistry. 53: 6412-20. PMID 20687610 DOI: 10.1021/jm100602m |
0.729 |
|
2009 |
Murage E, Beinborn M, Ahn JM. Seeking for alpha-helical propensity in a receptor-bound conformation of glucagon-like peptide-1. Advances in Experimental Medicine and Biology. 611: 289-90. PMID 19400196 |
0.729 |
|
2009 |
Ahn JM, Han SY, Murage E, Beinborn M. Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists. Advances in Experimental Medicine and Biology. 611: 125-6. PMID 19400122 |
0.709 |
|
2008 |
Murage EN, Schroeder JC, Beinborn M, Ahn JM. Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorganic & Medicinal Chemistry. 16: 10106-12. PMID 18952440 DOI: 10.1016/j.bmc.2008.10.006 |
0.729 |
|
2004 |
Ahn JM, Wentworth P, Janda KD. Probing lipase/esterase libraries for lipid A hydrolases--discovery of biocatalysts for the detoxification of bacterially-expressed recombinant protein. Chemical Communications (Cambridge, England). 364-5. PMID 14765210 DOI: 10.1039/B312662E |
0.34 |
|
2003 |
Moss JA, Coyle AR, Ahn JM, Meijler MM, Offer J, Janda KD. Tandem IMAC-HPLC purification of a cocaine-binding scFv antibody. Journal of Immunological Methods. 281: 143-8. PMID 14580888 DOI: 10.1016/J.Jim.2003.07.010 |
0.579 |
|
2003 |
Ahn JM, Wentworth P, Janda KD. Soluble polymer-supported convergent parallel library synthesis. Chemical Communications (Cambridge, England). 480-1. PMID 12638959 DOI: 10.1039/B210696E |
0.318 |
|
2003 |
Ying J, Ahn JM, Jacobsen NE, Brown MF, Hruby VJ. NMR solution structure of the glucagon antagonist [desHis1, desPhe6, Glu9]glucagon amide in the presence of perdeuterated dodecylphosphocholine micelles. Biochemistry. 42: 2825-35. PMID 12627948 DOI: 10.1021/Bi026629R |
0.613 |
|
2002 |
Ahn JM, Boyle NA, MacDonald MT, Janda KD. Peptidomimetics and peptide backbone modifications. Mini Reviews in Medicinal Chemistry. 2: 463-73. PMID 12370047 DOI: 10.2174/1389557023405828 |
0.456 |
|
2002 |
Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, Schuit F. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes. 51: 669-75. PMID 11872665 DOI: 10.2337/Diabetes.51.3.669 |
0.382 |
|
2002 |
Cowell SM, Balse-Srinivasan PM, Ahn JM, Hruby VJ. Design and synthesis of peptide antagonists and inverse agonists for G protein-coupled receptors. Methods in Enzymology. 343: 49-72. PMID 11665587 DOI: 10.1016/S0076-6879(02)43127-8 |
0.523 |
|
2001 |
Ahn JM, Gitu PM, Medeiros M, Swift JR, Trivedi D, Hruby VJ. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning. Journal of Medicinal Chemistry. 44: 3109-16. PMID 11543679 DOI: 10.1021/Jm010091Q |
0.55 |
|
2001 |
Ahn JM, Medeiros M, Trivedi D, Hruby VJ. Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. The Journal of Peptide Research : Official Journal of the American Peptide Society. 58: 151-8. PMID 11532074 DOI: 10.1034/J.1399-3011.2001.00880.X |
0.496 |
|
2001 |
Ahn JM, Medeiros M, Trivedi D, Hruby VJ. Development of potent truncated glucagon antagonists. Journal of Medicinal Chemistry. 44: 1372-9. PMID 11311060 DOI: 10.1021/Jm000453E |
0.544 |
|
2000 |
Trivedi D, Lin Y, Ahn JM, Siegel M, Mollova NN, Schram KH, Hruby VJ. Design and synthesis of conformationally constrained glucagon analogues. Journal of Medicinal Chemistry. 43: 1714-22. PMID 10794689 DOI: 10.1021/Jm990559D |
0.491 |
|
1998 |
Sturm NS, Lin Y, Burley SK, Krstenansky JL, Ahn JM, Azizeh BY, Trivedi D, Hruby VJ. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity. Journal of Medicinal Chemistry. 41: 2693-700. PMID 9667960 DOI: 10.1021/Jm980084A |
0.439 |
|
1997 |
Hruby VJ, Ahn JM, Liao S. Synthesis of oligopeptide and peptidomimetic libraries. Current Opinion in Chemical Biology. 1: 114-9. PMID 9667835 DOI: 10.1016/S1367-5931(97)80117-2 |
0.405 |
|
1997 |
Azizeh BY, Ahn JM, Caspari R, Shenderovich MD, Trivedi D, Hruby VJ. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon. Journal of Medicinal Chemistry. 40: 2555-62. PMID 9258362 DOI: 10.1021/Jm960800D |
0.433 |
|
Show low-probability matches. |